Genalyte Announces $44 Million Financing
News Aug 19, 2015
Genalyte, Inc. HAS announced it has completed a Series C Financing round of $44 million, led by Khosla Ventures. The company is redefining diagnostics with a testing platform and microchip technology that can be utilized in physician offices. With the application of a single drop of blood to a silicon microchip, Genalyte’s Maverick Detection System can offer a complete panel of diagnostic test results in fifteen minutes.
“We believe there is an enormous opportunity to improve our healthcare system by providing diagnostic results at the time and place they need to be delivered – when the patient is sitting in front of the doctor,” said CEO Cary Gunn. “Our technology allows us to eliminate a number of inefficiencies from the system, such as the secondary appointment to have blood drawn, the large quantity of blood required, the long wait for results, and the game of phone tag you play with your doctor when results finally do arrive.”
Previous investors at the Redmile Group, Claremont Creek Ventures, BioMed Ventures, and Pura Vida Investments joined Khosla Ventures in the latest financing round.
“We at Khosla Ventures believe that timely access to more diagnostic and health data, combined with computational tools to digest this information will create more efficient medicine and provide better healthcare,” said Vinod Khosla, founder of Khosla Ventures. “We assessed a large number of emerging diagnostic technologies and believe that Genalyte has the potential to fuel this transition.”
The company intends to utilize the funding to refine the existing Maverick platform for the physician office setting, and to perform the clinical studies required to prove the accuracy of the device and suitability for use in a near-patient setting.
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Pap Test Fluids Used to Test for Endometrial & Ovarian CancersNews
Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.